Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...
Novartis already received FDA approval of ITVISMA as a gene therapy for the treatment of patients with SMA. Read why NVS ...
Unavailable partners intensify desire because scarcity fuels longing while imagination fills the gaps left by reality.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results